RxDoctor Payments Data

Tasha Bollin

Family · Goldsboro, NCNPI 1982112066

Payments from drug & device makers

$4,834in general payments, 2019–2025

Across 274 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$418
  • AstraZeneca$416
  • AbbVie$383
  • Lilly USA, LLC$285
  • Lundbeck LLC$277
  • GSK$272
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$4,834100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,834 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$86,354
Medicare patients
274
Services billed
1,132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$53,606
RybelsusSemaglutide33$42,883
JardianceEmpagliflozin33$39,532
JanuviaSitagliptin Phosphate26$29,401
EliquisApixaban28$28,660
MounjaroTirzepatide23$28,435
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$21,952
FarxigaDapagliflozin Propanediol21$17,101
LinzessLinaclotide12$13,708
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$7,897
Breo ElliptaFluticasone/Vilanterol18$7,861
Combivent RespimatIpratropium/Albuterol Sulfate12$5,643
Rosuvastatin Calcium268$3,366
Atorvastatin Calcium270$2,803
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$2,760

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$266$96,48970 claims
Boehringer IngelheimJardiance, Combivent Respimat$118$45,17545 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$272$37,71071 claims
MerckJanuvia$121$29,40126 claims
PfizerEliquis$47$28,66028 claims
Lilly USA, LLCMounjaro$285$28,43523 claims
AstraZenecaFarxiga$416$17,10121 claims
AbbVieLinzess$383$13,70812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.

Other family in Goldsboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →